InflammX Therapeutics, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 2020-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://inflammx.com
Clinical Trials
1
Active:0
Completed:0
Trial Phases
1 Phases
Phase 2:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials
Phase 2
1 (100.0%)Study of Xiflam™ Treatment in Patients Post COVID-19 Infection Suffering from What is Known As Long COVID (LC)
- First Posted Date
- 2024-05-31
- Last Posted Date
- 2025-02-25
- Lead Sponsor
- Inflammx Therapeutics Inc
- Target Recruit Count
- 15
- Registration Number
- NCT06437223
- Locations
- 🇺🇸
Massachusetts Eye Research and Surgery Institution (MERSI), Waltham, Massachusetts, United States
News
No news found